The Therapeutic Efficacy of Curcumin vs. Metformin in Modulating the Gut Microbiota in NAFLD Rats: A Comparative Study

Structural disruption of gut microbiota is closely related to the occurrence of non-alcoholic fatty liver disease (NAFLD). Previous research has demonstrated that both curcumin (CUR) and metformin (MET) have a therapeutic effect against NAFLD and play a role in modulating the gut microbiota. However...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in microbiology Vol. 11; p. 555293
Main Authors Li, Ruifang, Yao, Yurong, Gao, Pengfei, Bu, Shurui
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 14.01.2021
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Structural disruption of gut microbiota is closely related to the occurrence of non-alcoholic fatty liver disease (NAFLD). Previous research has demonstrated that both curcumin (CUR) and metformin (MET) have a therapeutic effect against NAFLD and play a role in modulating the gut microbiota. However, there is a lack of direct comparison between the two medications in terms of the therapeutic efficacy and the regulatory effect on gut microbiota. In this study, we administered either CUR or MET to rats with high-fat diet (HFD)-induced obesity to observe changes in body parameters, biochemical parameters, liver, and ileum pathology and gut microbiota, and used next generation sequencing and multivariate analysis to evaluate the structural changes of gut microbiota in a NAFLD rat model before and after CUR and MET intervention. It was found that both CUR and MET attenuated hepatic ectopic fat deposition, alleviated inflammatory factors, and improved intestinal barrier integrity in HFD-fed rats. More importantly, CUR and MET reduced the Firmicutes/Bacteroidetes ratio and reverted the composition of the HFD-disrupted gut microbiota. Both CUR and MET treatments effectively modified the gut microbiome, enriched the abundance of beneficial bacteria and reduced opportunistic pathogens in obese rats. The abundance of Butyricicoccus was increased while the abundance of Dorea was decreased in HFD + CUR group. Besides, some beneficial bacteria such as Prevotella were increased in MET-treated animals. Spearman’s correlation analysis showed that Helicobacter, Akkermansia, Desulfovibrio, Romboutsia, Corynebacterium, Lactobacillus, Ruminococcaceae_ unclassified, Lachnospiraceae_unclassified , and Clostridiales_unclassified showed significantly positive correlations with TG, TC, LDL-C, GLU, IL-6, IL-1β, and TNF-α, and negative correlations with HDL-C (both p < 0.05). However, Prevotella and Stomatobaculum showed an opposite trend. In summary, CUR and MET showed similar effects in alleviating hepatic steatosis, improving intestinal barrier integrity and modulating gut microbiota in HFD-induced obesity rats, and therefore may prove to be a novel adjunctive therapy for NAFLD.
AbstractList Structural disruption of gut microbiota is closely related to the occurrence of non-alcoholic fatty liver disease (NAFLD). Previous research has demonstrated that both curcumin (CUR) and metformin (MET) have a therapeutic effect against NAFLD and play a role in modulating the gut microbiota. However, there is a lack of direct comparison between the two medications in terms of the therapeutic efficacy and the regulatory effect on gut microbiota. In this study, we administered either CUR or MET to rats with high-fat diet (HFD)-induced obesity to observe changes in body parameters, biochemical parameters, liver, and ileum pathology and gut microbiota, and used next generation sequencing and multivariate analysis to evaluate the structural changes of gut microbiota in a NAFLD rat model before and after CUR and MET intervention. It was found that both CUR and MET attenuated hepatic ectopic fat deposition, alleviated inflammatory factors, and improved intestinal barrier integrity in HFD-fed rats. More importantly, CUR and MET reduced the Firmicutes/Bacteroidetes ratio and reverted the composition of the HFD-disrupted gut microbiota. Both CUR and MET treatments effectively modified the gut microbiome, enriched the abundance of beneficial bacteria and reduced opportunistic pathogens in obese rats. The abundance of Butyricicoccus was increased while the abundance of Dorea was decreased in HFD + CUR group. Besides, some beneficial bacteria such as Prevotella were increased in MET-treated animals. Spearman’s correlation analysis showed that Helicobacter, Akkermansia, Desulfovibrio, Romboutsia, Corynebacterium, Lactobacillus, Ruminococcaceae_unclassified, Lachnospiraceae_unclassified, and Clostridiales_unclassified showed significantly positive correlations with TG, TC, LDL-C, GLU, IL-6, IL-1β, and TNF-α, and negative correlations with HDL-C (both p < 0.05). However, Prevotella and Stomatobaculum showed an opposite trend. In summary, CUR and MET showed similar effects in alleviating hepatic steatosis, improving intestinal barrier integrity and modulating gut microbiota in HFD-induced obesity rats, and therefore may prove to be a novel adjunctive therapy for NAFLD.
Structural disruption of gut microbiota is closely related to the occurrence of non-alcoholic fatty liver disease (NAFLD). Previous research has demonstrated that both curcumin (CUR) and metformin (MET) have a therapeutic effect against NAFLD and play a role in modulating the gut microbiota. However, there is a lack of direct comparison between the two medications in terms of the therapeutic efficacy and the regulatory effect on gut microbiota. In this study, we administered either CUR or MET to rats with high-fat diet (HFD)-induced obesity to observe changes in body parameters, biochemical parameters, liver, and ileum pathology and gut microbiota, and used next generation sequencing and multivariate analysis to evaluate the structural changes of gut microbiota in a NAFLD rat model before and after CUR and MET intervention. It was found that both CUR and MET attenuated hepatic ectopic fat deposition, alleviated inflammatory factors, and improved intestinal barrier integrity in HFD-fed rats. More importantly, CUR and MET reduced the Firmicutes/Bacteroidetes ratio and reverted the composition of the HFD-disrupted gut microbiota. Both CUR and MET treatments effectively modified the gut microbiome, enriched the abundance of beneficial bacteria and reduced opportunistic pathogens in obese rats. The abundance of Butyricicoccus was increased while the abundance of Dorea was decreased in HFD + CUR group. Besides, some beneficial bacteria such as Prevotella were increased in MET-treated animals. Spearman's correlation analysis showed that Helicobacter, Akkermansia, Desulfovibrio, Romboutsia, Corynebacterium, Lactobacillus, Ruminococcaceae_unclassified, Lachnospiraceae_unclassified, and Clostridiales_unclassified showed significantly positive correlations with TG, TC, LDL-C, GLU, IL-6, IL-1β, and TNF-α, and negative correlations with HDL-C (both p < 0.05). However, Prevotella and Stomatobaculum showed an opposite trend. In summary, CUR and MET showed similar effects in alleviating hepatic steatosis, improving intestinal barrier integrity and modulating gut microbiota in HFD-induced obesity rats, and therefore may prove to be a novel adjunctive therapy for NAFLD.Structural disruption of gut microbiota is closely related to the occurrence of non-alcoholic fatty liver disease (NAFLD). Previous research has demonstrated that both curcumin (CUR) and metformin (MET) have a therapeutic effect against NAFLD and play a role in modulating the gut microbiota. However, there is a lack of direct comparison between the two medications in terms of the therapeutic efficacy and the regulatory effect on gut microbiota. In this study, we administered either CUR or MET to rats with high-fat diet (HFD)-induced obesity to observe changes in body parameters, biochemical parameters, liver, and ileum pathology and gut microbiota, and used next generation sequencing and multivariate analysis to evaluate the structural changes of gut microbiota in a NAFLD rat model before and after CUR and MET intervention. It was found that both CUR and MET attenuated hepatic ectopic fat deposition, alleviated inflammatory factors, and improved intestinal barrier integrity in HFD-fed rats. More importantly, CUR and MET reduced the Firmicutes/Bacteroidetes ratio and reverted the composition of the HFD-disrupted gut microbiota. Both CUR and MET treatments effectively modified the gut microbiome, enriched the abundance of beneficial bacteria and reduced opportunistic pathogens in obese rats. The abundance of Butyricicoccus was increased while the abundance of Dorea was decreased in HFD + CUR group. Besides, some beneficial bacteria such as Prevotella were increased in MET-treated animals. Spearman's correlation analysis showed that Helicobacter, Akkermansia, Desulfovibrio, Romboutsia, Corynebacterium, Lactobacillus, Ruminococcaceae_unclassified, Lachnospiraceae_unclassified, and Clostridiales_unclassified showed significantly positive correlations with TG, TC, LDL-C, GLU, IL-6, IL-1β, and TNF-α, and negative correlations with HDL-C (both p < 0.05). However, Prevotella and Stomatobaculum showed an opposite trend. In summary, CUR and MET showed similar effects in alleviating hepatic steatosis, improving intestinal barrier integrity and modulating gut microbiota in HFD-induced obesity rats, and therefore may prove to be a novel adjunctive therapy for NAFLD.
Structural disruption of gut microbiota is closely related to the occurrence of non-alcoholic fatty liver disease (NAFLD). Previous research has demonstrated that both curcumin (CUR) and metformin (MET) have a therapeutic effect against NAFLD and play a role in modulating the gut microbiota. However, there is a lack of direct comparison between the two medications in terms of the therapeutic efficacy and the regulatory effect on gut microbiota. In this study, we administered either CUR or MET to rats with high-fat diet (HFD)-induced obesity to observe changes in body parameters, biochemical parameters, liver, and ileum pathology and gut microbiota, and used next generation sequencing and multivariate analysis to evaluate the structural changes of gut microbiota in a NAFLD rat model before and after CUR and MET intervention. It was found that both CUR and MET attenuated hepatic ectopic fat deposition, alleviated inflammatory factors, and improved intestinal barrier integrity in HFD-fed rats. More importantly, CUR and MET reduced the Firmicutes/Bacteroidetes ratio and reverted the composition of the HFD-disrupted gut microbiota. Both CUR and MET treatments effectively modified the gut microbiome, enriched the abundance of beneficial bacteria and reduced opportunistic pathogens in obese rats. The abundance of Butyricicoccus was increased while the abundance of Dorea was decreased in HFD + CUR group. Besides, some beneficial bacteria such as Prevotella were increased in MET-treated animals. Spearman’s correlation analysis showed that Helicobacter, Akkermansia, Desulfovibrio, Romboutsia, Corynebacterium, Lactobacillus, Ruminococcaceae_ unclassified, Lachnospiraceae_unclassified , and Clostridiales_unclassified showed significantly positive correlations with TG, TC, LDL-C, GLU, IL-6, IL-1β, and TNF-α, and negative correlations with HDL-C (both p < 0.05). However, Prevotella and Stomatobaculum showed an opposite trend. In summary, CUR and MET showed similar effects in alleviating hepatic steatosis, improving intestinal barrier integrity and modulating gut microbiota in HFD-induced obesity rats, and therefore may prove to be a novel adjunctive therapy for NAFLD.
Structural disruption of gut microbiota is closely related to the occurrence of non-alcoholic fatty liver disease (NAFLD). Previous research has demonstrated that both curcumin (CUR) and metformin (MET) have a therapeutic effect against NAFLD and play a role in modulating the gut microbiota. However, there is a lack of direct comparison between the two medications in terms of the therapeutic efficacy and the regulatory effect on gut microbiota. In this study, we administered either CUR or MET to rats with high-fat diet (HFD)-induced obesity to observe changes in body parameters, biochemical parameters, liver, and ileum pathology and gut microbiota, and used next generation sequencing and multivariate analysis to evaluate the structural changes of gut microbiota in a NAFLD rat model before and after CUR and MET intervention. It was found that both CUR and MET attenuated hepatic ectopic fat deposition, alleviated inflammatory factors, and improved intestinal barrier integrity in HFD-fed rats. More importantly, CUR and MET reduced the ratio and reverted the composition of the HFD-disrupted gut microbiota. Both CUR and MET treatments effectively modified the gut microbiome, enriched the abundance of beneficial bacteria and reduced opportunistic pathogens in obese rats. The abundance of was increased while the abundance of was decreased in HFD + CUR group. Besides, some beneficial bacteria such as were increased in MET-treated animals. Spearman's correlation analysis showed that unclassified, , and showed significantly positive correlations with TG, TC, LDL-C, GLU, IL-6, IL-1β, and TNF-α, and negative correlations with HDL-C (both < 0.05). However, and showed an opposite trend. In summary, CUR and MET showed similar effects in alleviating hepatic steatosis, improving intestinal barrier integrity and modulating gut microbiota in HFD-induced obesity rats, and therefore may prove to be a novel adjunctive therapy for NAFLD.
Author Li, Ruifang
Gao, Pengfei
Bu, Shurui
Yao, Yurong
AuthorAffiliation 2 Department of Infection, Jinshan Hospital Affiliated to Fudan University , Shanghai , China
3 Department of Traditional Chinese Medicine, Jinshan Hospital Affiliated to Fudan University , Shanghai , China
1 Department of Gastroenterology, Jinshan Hospital Affiliated to Fudan University , Shanghai , China
AuthorAffiliation_xml – name: 1 Department of Gastroenterology, Jinshan Hospital Affiliated to Fudan University , Shanghai , China
– name: 3 Department of Traditional Chinese Medicine, Jinshan Hospital Affiliated to Fudan University , Shanghai , China
– name: 2 Department of Infection, Jinshan Hospital Affiliated to Fudan University , Shanghai , China
Author_xml – sequence: 1
  givenname: Ruifang
  surname: Li
  fullname: Li, Ruifang
– sequence: 2
  givenname: Yurong
  surname: Yao
  fullname: Yao, Yurong
– sequence: 3
  givenname: Pengfei
  surname: Gao
  fullname: Gao, Pengfei
– sequence: 4
  givenname: Shurui
  surname: Bu
  fullname: Bu, Shurui
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33584555$$D View this record in MEDLINE/PubMed
BookMark eNp9UstuEzEUtVARLaUfwAZ5ySapH-MZDwukKPQlJSBBkdhZHj9SVzPj4Eek_D2eplQtCyxbfp1zrq_veQuORj8aAN5jNKeUt-d2cKqbE0TQnDFGWvoKnOC6rmYUkV9Hz9bH4CzGe1RaVcAIvQHHlDJeFdYJ2N3eGVhGkFuTk1PwwlqnpNpDb-EyB5UHN8JdnMO1SdaHaVf62uvcy-TGDUxF4ConuHYq-M75JCfA18Xl6gv8LlP8BBdw6YetDAW_M_BHynr_Dry2so_m7HE-BT8vL26X17PVt6ub5WI1U4ziNGMEaYpoXVuGtakI00jXpOTKGsSk6jqjSh66xp3hXWtJQ3glGZnICBFM6Cm4OehqL-_FNrhBhr3w0omHAx82QoaSdm-ExpJRZBgnLSkiWqq6w5zyTtZGW6uL1ueD1jZ3g9HKjCnI_oXoy5vR3YmN34mGNxVpWBH4-CgQ_O9sYhKDi8r0vRyNz1GQiresZYzXBfrheaynIH8LVwD4ACifHmMw9gmCkZj8IR78ISZ_iIM_Cqf5h6NcKkXx03Nd_x_mHxQAwGs
CitedBy_id crossref_primary_10_1007_s00774_021_01247_w
crossref_primary_10_3389_fnut_2022_960309
crossref_primary_10_3390_toxins14120859
crossref_primary_10_1111_jcmm_17631
crossref_primary_10_1080_10408398_2023_2204349
crossref_primary_10_3390_ani13223575
crossref_primary_10_18632_aging_203821
crossref_primary_10_3390_nu15030743
crossref_primary_10_3390_ani14081223
crossref_primary_10_3389_fmicb_2023_1274559
crossref_primary_10_1016_j_phrs_2023_106679
crossref_primary_10_3389_fmicb_2022_925929
crossref_primary_10_3390_ijms24054603
crossref_primary_10_1093_femsle_fnad016
crossref_primary_10_3389_fcvm_2022_972603
crossref_primary_10_1039_D4FO01813C
crossref_primary_10_1515_tjb_2024_0027
crossref_primary_10_3390_ijms25147710
crossref_primary_10_3389_fcimb_2024_1323261
crossref_primary_10_3389_fphar_2023_1163694
crossref_primary_10_3390_nu16162644
crossref_primary_10_1002_ptr_7681
crossref_primary_10_1089_met_2022_0105
crossref_primary_10_3390_microorganisms10071281
crossref_primary_10_1002_fsn3_4178
crossref_primary_10_1039_D1FO02481G
crossref_primary_10_3389_fmicb_2022_1051200
crossref_primary_10_1016_j_foodchem_2024_140514
crossref_primary_10_3389_fphar_2024_1343193
crossref_primary_10_3390_nu13093289
crossref_primary_10_3390_nu15081989
crossref_primary_10_26599_FSHW_2022_9250218
crossref_primary_10_3390_nu15245053
crossref_primary_10_1007_s00210_023_02520_7
crossref_primary_10_1007_s12029_022_00809_z
Cites_doi 10.1126/science.1241165
10.1038/s41598-019-38874-3
10.1016/j.bbagen.2017.03.017
10.1038/s41591-018-0222-4
10.1152/ajpendo.00285.2017
10.1038/nature11450
10.1002/hep.28431
10.1016/j.cell.2014.05.052
10.1136/gut.2010.215665
10.1002/hep.26225
10.1038/s41366-018-0290-z
10.1111/j.1365-2672.1991.tb02739.x
10.3390/ijms19103075
10.1371/journal.pone.0020944
10.3390/nu9101124
10.1007/s00535-017-1415-1
10.1053/gast.1996.v110.pm8964397
10.1136/gutjnl-2019-319726
10.1128/aem.01541-9
10.1038/nrgastro.2017.109
10.1038/srep14405
10.1586/17474124.2015.1051029
10.1038/nrgastro.2016.85
10.1016/j.biopha.2019.109131
10.1007/s00125-017-4342-z
10.1007/s10620-016-4045-1
10.1017/s0007114519001508
10.3390/md17080455
10.1136/gutjnl-2012-303839
10.1016/j.metabol.2017.12.009
10.5152/tjg.2017.17033
10.1152/ajpendo.00107.2017
10.1038/ismej.2014.177
10.4254/wjh.v7.i12.1679
10.1093/bioinformatics/btr507
10.1021/acs.jafc.9b00249
10.1016/j.arteri.2018.03.004
10.4254/wjh.v11.i8.619
10.1155/2018/7261619
10.1155/2018/9734845
10.1002/mnfr.200500013
10.3390/nu11112642
10.1016/j.ctim.2020.102322
10.1039/c7fo01346a
10.1002/hep.26093
10.1038/s41598-019-49462-w
10.1038/nature08530
10.1042/cs20080253
ContentType Journal Article
Copyright Copyright © 2021 Li, Yao, Gao and Bu.
Copyright © 2021 Li, Yao, Gao and Bu. 2021 Li, Yao, Gao and Bu
Copyright_xml – notice: Copyright © 2021 Li, Yao, Gao and Bu.
– notice: Copyright © 2021 Li, Yao, Gao and Bu. 2021 Li, Yao, Gao and Bu
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.3389/fmicb.2020.555293
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
CrossRef
PubMed

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1664-302X
ExternalDocumentID oai_doaj_org_article_d1a530e582924a5dac6b1838ba6edffd
PMC7874275
33584555
10_3389_fmicb_2020_555293
Genre Journal Article
GrantInformation_xml – fundername: Science and Technology Commission of Shanghai Municipality
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
ECGQY
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
O5R
O5S
OK1
PGMZT
RNS
RPM
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c531t-520d30366f51de425d0d622935705acbbec845d61be8b9f27284a52c531002123
IEDL.DBID M48
ISSN 1664-302X
IngestDate Wed Aug 27 01:30:45 EDT 2025
Thu Aug 21 18:18:23 EDT 2025
Fri Jul 11 16:12:19 EDT 2025
Mon Jul 21 06:06:51 EDT 2025
Thu Apr 24 22:51:19 EDT 2025
Tue Jul 01 01:12:52 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords metformin
non-alcoholic fatty liver disease
short-chain fatty acids
gut microbiota
curcumin
Language English
License Copyright © 2021 Li, Yao, Gao and Bu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c531t-520d30366f51de425d0d622935705acbbec845d61be8b9f27284a52c531002123
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Gislane Lelis Vilela de Oliveira, São Paulo State University, Brazil; Hein Min Tun, The University of Hong Kong, Hong Kong
This article was submitted to Systems Microbiology, a section of the journal Frontiers in Microbiology
Edited by: Koichi Tamano, National Institute of Advanced Industrial Science and Technology (AIST), Japan
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fmicb.2020.555293
PMID 33584555
PQID 2489595586
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_d1a530e582924a5dac6b1838ba6edffd
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7874275
proquest_miscellaneous_2489595586
pubmed_primary_33584555
crossref_primary_10_3389_fmicb_2020_555293
crossref_citationtrail_10_3389_fmicb_2020_555293
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-01-14
PublicationDateYYYYMMDD 2021-01-14
PublicationDate_xml – month: 01
  year: 2021
  text: 2021-01-14
  day: 14
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in microbiology
PublicationTitleAlternate Front Microbiol
PublicationYear 2021
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Hu (B15) 2019; 17
Li (B19) 2018; 19
Lin (B20) 2019; 67
Qin (B30) 2012; 490
Jin (B16) 2018; 314
Cummings (B8) 1991; 70
Leung (B18) 2016; 13
Neyrinck (B27) 2011; 6
Saberi-Karimian (B33) 2020; 49
Younossi (B44) 2016; 64
Smith (B36) 2013; 341
Younossi (B43) 2018; 15
Zhang (B46) 2019; 118
Byrne (B4) 2009; 116
Maslowski (B23) 2009; 461
Mathur (B24) 2015; 9
Cox (B7) 2014; 158
Tang (B39) 2018; 2018
Zeng (B45) 2019; 9
Ferguson (B11) 2018; 82
Ma (B21) 2017; 9
Carrera-Quintanar (B5) 2018; 2018
Murphy (B26) 2010; 59
Zhang (B47) 2015; 5
Chen (B6) 2018; 9
Sun (B38) 2018; 24
Xu (B42) 2015; 9
Galvez (B13) 2005; 49
Magoč (B22) 2011; 27
Granado-Serrano (B14) 2019; 9
Rodriguez (B32) 2020; 69
Karvonen (B17) 2019; 43
Feng (B10) 2017; 1861
Velazquez (B41) 2019; 11
Meroni (B25) 2019; 11
Schloss (B34) 2009; 75
Rena (B31) 2017; 60
Bechmann (B3) 2013; 57
Abdou (B1) 2016; 61
Sumida (B37) 2018; 53
D’Argenio (B9) 1996; 110
Zhu (B48) 2013; 57
Fontané (B12) 2018; 30
Niu (B28) 2019; 122
Özkul (B29) 2017; 28
Shin (B35) 2014; 63
Van Hul (B40) 2018; 314
Abdul-Hai (B2) 2015; 7
References_xml – volume: 341
  start-page: 569
  year: 2013
  ident: B36
  article-title: The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis.
  publication-title: Science
  doi: 10.1126/science.1241165
– volume: 9
  year: 2019
  ident: B14
  article-title: Faecal bacterial and short-chain fatty acids signature in hypercholesterolemia.
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-019-38874-3
– volume: 1861
  start-page: 1801
  year: 2017
  ident: B10
  article-title: Modulation of gut microbiota contributes to curcumin-mediated attenuation of hepatic steatosis in rats.
  publication-title: Biochim. Biophys. Acta
  doi: 10.1016/j.bbagen.2017.03.017
– volume: 24
  start-page: 1919
  year: 2018
  ident: B38
  article-title: Gut microbiota and intestinal FXR mediate the clinical benefits of metformin.
  publication-title: Nat. Med.
  doi: 10.1038/s41591-018-0222-4
– volume: 314
  start-page: E201
  year: 2018
  ident: B16
  article-title: Curcumin and other dietary polyphenols: potential mechanisms of metabolic actions and therapy for diabetes and obesity.
  publication-title: Am. J. Physiol. Endocrinol. Metab.
  doi: 10.1152/ajpendo.00285.2017
– volume: 490
  start-page: 55
  year: 2012
  ident: B30
  article-title: A metagenome-wide association study of gut microbiota in type 2 diabetes.
  publication-title: Nature
  doi: 10.1038/nature11450
– volume: 64
  start-page: 73
  year: 2016
  ident: B44
  article-title: Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes.
  publication-title: Hepatology
  doi: 10.1002/hep.28431
– volume: 158
  start-page: 705
  year: 2014
  ident: B7
  article-title: Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences.
  publication-title: Cell
  doi: 10.1016/j.cell.2014.05.052
– volume: 59
  start-page: 1635
  year: 2010
  ident: B26
  article-title: Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models.
  publication-title: Gut
  doi: 10.1136/gut.2010.215665
– volume: 57
  start-page: 1394
  year: 2013
  ident: B3
  article-title: Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis.
  publication-title: Hepatology
  doi: 10.1002/hep.26225
– volume: 43
  start-page: 713
  year: 2019
  ident: B17
  article-title: Gut microbiota and overweight in 3-year old children.
  publication-title: Int. J. Obes.
  doi: 10.1038/s41366-018-0290-z
– volume: 70
  start-page: 443
  year: 1991
  ident: B8
  article-title: The control and consequences of bacterial fermentation in the human colon.
  publication-title: J. Appl. Bacteriol.
  doi: 10.1111/j.1365-2672.1991.tb02739.x
– volume: 19
  year: 2018
  ident: B19
  article-title: Regulatory efficacy of the polyunsaturated fatty acids from microalgae spirulina platensis on lipid metabolism and gut microbiota in high-fat diet rats.
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms19103075
– volume: 6
  year: 2011
  ident: B27
  article-title: Prebiotic effects of wheat arabinoxylan related to the increase in bifidobacteria, Roseburia and Bacteroides/Prevotella in diet-induced obese mice.
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0020944
– volume: 9
  year: 2017
  ident: B21
  article-title: Gut microbiota and nonalcoholic fatty liver disease: insights on mechanisms and therapy.
  publication-title: Nutrients
  doi: 10.3390/nu9101124
– volume: 53
  start-page: 362
  year: 2018
  ident: B37
  article-title: Current and future pharmacological therapies for NAFLD/NASH.
  publication-title: J. Gastroenterol.
  doi: 10.1007/s00535-017-1415-1
– volume: 110
  start-page: 1727
  year: 1996
  ident: B9
  article-title: Butyrate enemas in experimental colitis and protection against large bowel cancer in a rat model.
  publication-title: Gastroenterology
  doi: 10.1053/gast.1996.v110.pm8964397
– volume: 69
  start-page: 1975
  year: 2020
  ident: B32
  article-title: Discovery of the gut microbial signature driving the efficacy of prebiotic intervention in obese patients.
  publication-title: Gut
  doi: 10.1136/gutjnl-2019-319726
– volume: 75
  start-page: 7537
  year: 2009
  ident: B34
  article-title: Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities.
  publication-title: Appl. Environ. Microbiol.
  doi: 10.1128/aem.01541-9
– volume: 15
  start-page: 11
  year: 2018
  ident: B43
  article-title: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.
  publication-title: Nat. Rev. Gastroenterol. Hepatol.
  doi: 10.1038/nrgastro.2017.109
– volume: 5
  year: 2015
  ident: B47
  article-title: Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats.
  publication-title: Sci. Rep.
  doi: 10.1038/srep14405
– volume: 9
  start-page: 1087
  year: 2015
  ident: B24
  article-title: Obesity and the microbiome.
  publication-title: Expert. Rev. Gastroenterol. Hepatol.
  doi: 10.1586/17474124.2015.1051029
– volume: 13
  start-page: 412
  year: 2016
  ident: B18
  article-title: The role of the gut microbiota in NAFLD.
  publication-title: Nat. Rev. Gastroenterol. Hepatol.
  doi: 10.1038/nrgastro.2016.85
– volume: 118
  year: 2019
  ident: B46
  article-title: Effects of berberine and metformin on intestinal inflammation and gut microbiome composition in db/db mice.
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2019.109131
– volume: 60
  start-page: 1577
  year: 2017
  ident: B31
  article-title: The mechanisms of action of metformin.
  publication-title: Diabetologia
  doi: 10.1007/s00125-017-4342-z
– volume: 61
  start-page: 1268
  year: 2016
  ident: B1
  article-title: Gut Microbiota of nonalcoholic fatty liver disease.
  publication-title: Dig. Dis. Sci.
  doi: 10.1007/s10620-016-4045-1
– volume: 122
  start-page: 616
  year: 2019
  ident: B28
  article-title: Curcumin attenuates insulin resistance and hepatic lipid accumulation in a rat model of intra-uterine growth restriction through insulin signalling pathway and sterol regulatory element binding proteins.
  publication-title: Br. J. Nutr.
  doi: 10.1017/s0007114519001508
– volume: 17
  year: 2019
  ident: B15
  article-title: Long-chain bases from sea cucumber alleviate obesity by modulating gut microbiota.
  publication-title: Mar. Drugs
  doi: 10.3390/md17080455
– volume: 63
  start-page: 727
  year: 2014
  ident: B35
  article-title: An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice.
  publication-title: Gut
  doi: 10.1136/gutjnl-2012-303839
– volume: 82
  start-page: 22
  year: 2018
  ident: B11
  article-title: Curcumin potentiates cholesterol-lowering effects of phytosterols in hypercholesterolaemic individuals. A randomised controlled trial.
  publication-title: Metabolism
  doi: 10.1016/j.metabol.2017.12.009
– volume: 28
  start-page: 361
  year: 2017
  ident: B29
  article-title: Determination of certain bacterial groups in gut microbiota and endotoxin levels in patients with nonalcoholic steatohepatitis.
  publication-title: Turk J. Gastroenterol.
  doi: 10.5152/tjg.2017.17033
– volume: 314
  start-page: E334
  year: 2018
  ident: B40
  article-title: Reduced obesity, diabetes, and steatosis upon cinnamon and grape pomace are associated with changes in gut microbiota and markers of gut barrier.
  publication-title: Am. J. Physiol. Endocrinol. Metab.
  doi: 10.1152/ajpendo.00107.2017
– volume: 9
  start-page: 552
  year: 2015
  ident: B42
  article-title: Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal formula.
  publication-title: ISME J.
  doi: 10.1038/ismej.2014.177
– volume: 7
  start-page: 1679
  year: 2015
  ident: B2
  article-title: Influence of gut bacteria on development and progression of non-alcoholic fatty liver disease.
  publication-title: World J. Hepatol.
  doi: 10.4254/wjh.v7.i12.1679
– volume: 27
  start-page: 2957
  year: 2011
  ident: B22
  article-title: FLASH: fast length adjustment of short reads to improve genome assemblies.
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btr507
– volume: 67
  start-page: 3624
  year: 2019
  ident: B20
  article-title: Alterations of bile acids and gut microbiota in obesity induced by high fat diet in rat model.
  publication-title: J. Agric. Food Chem.
  doi: 10.1021/acs.jafc.9b00249
– volume: 30
  start-page: 271
  year: 2018
  ident: B12
  article-title: Influence of the microbiota and probiotics in obesity.
  publication-title: Clin. Investig. Arterioscler.
  doi: 10.1016/j.arteri.2018.03.004
– volume: 11
  start-page: 619
  year: 2019
  ident: B41
  article-title: Prolonged high-fat-diet feeding promotes non-alcoholic fatty liver disease and alters gut microbiota in mice.
  publication-title: World J. Hepatol.
  doi: 10.4254/wjh.v11.i8.619
– volume: 2018
  year: 2018
  ident: B39
  article-title: Modulation of the gut microbiota in rats by hugan qingzhi tablets during the treatment of high-fat-diet-induced nonalcoholic fatty liver Disease.
  publication-title: Oxid. Med. Cell Longev.
  doi: 10.1155/2018/7261619
– volume: 2018
  year: 2018
  ident: B5
  article-title: Phytochemicals that influence gut microbiota as prophylactics and for the treatment of obesity and inflammatory diseases.
  publication-title: Mediators Inflamm.
  doi: 10.1155/2018/9734845
– volume: 49
  start-page: 601
  year: 2005
  ident: B13
  article-title: Effects of dietary fiber on inflammatory bowel disease.
  publication-title: Mol. Nutr. Food Res.
  doi: 10.1002/mnfr.200500013
– volume: 11
  year: 2019
  ident: B25
  article-title: The role of probiotics in nonalcoholic fatty liver disease: a new insight into therapeutic strategies.
  publication-title: Nutrients
  doi: 10.3390/nu11112642
– volume: 49
  year: 2020
  ident: B33
  article-title: Effects of curcuminoids on inflammatory status in patients with non-alcoholic fatty liver disease: a randomized controlled trial.
  publication-title: Complement. Ther. Med.
  doi: 10.1016/j.ctim.2020.102322
– volume: 9
  start-page: 3732
  year: 2018
  ident: B6
  article-title: Modulation of gut microbiota by mulberry fruit polysaccharide treatment of obese diabetic db/db mice.
  publication-title: Food Funct.
  doi: 10.1039/c7fo01346a
– volume: 57
  start-page: 601
  year: 2013
  ident: B48
  article-title: Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH.
  publication-title: Hepatology
  doi: 10.1002/hep.26093
– volume: 9
  year: 2019
  ident: B45
  article-title: Discrepant gut microbiota markers for the classification of obesity-related metabolic abnormalities.
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-019-49462-w
– volume: 461
  start-page: 1282
  year: 2009
  ident: B23
  article-title: Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43.
  publication-title: Nature
  doi: 10.1038/nature08530
– volume: 116
  start-page: 539
  year: 2009
  ident: B4
  article-title: Metabolic disturbances in non-alcoholic fatty liver disease.
  publication-title: Clin. Sci.
  doi: 10.1042/cs20080253
SSID ssj0000402000
Score 2.4738944
Snippet Structural disruption of gut microbiota is closely related to the occurrence of non-alcoholic fatty liver disease (NAFLD). Previous research has demonstrated...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 555293
SubjectTerms curcumin
gut microbiota
metformin
Microbiology
non-alcoholic fatty liver disease
short-chain fatty acids
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlEOil9F33EVToqeDUli1Z7m2zyTaUbg4lgdzE6OF2IfWWrB3Yf98Z2dnsltJeCr7YluzB34xmBo2_Yexd3uSFr3VIK2UxQQFrU3BOpspBDU4JLyJZ9fxMnV6Uny_l5VarL6oJG-iBhw_3wecgiyxILTBTAOnxARbVUFtQwTeNp9UXfd5WMhXXYEqLsnEbE7OwGmFaOIv5oMgOpZSiLnYcUeTr_1OQ-Xut5JbzmT1kD8aokU8GaR-xe6F9zPaHPpLrJ-wGwebnd39S8RMihgC35suGT_tr1_9YtPxmdcjnoaMoFc_wmC99bN7VfuMYBvJPfcfni4GYqQMacDaZfTnmX6FbfeQTPr0jCudUfrh-yi5mJ-fT03RsqJA6NLUOk87Mk8tSjcx9QGv1mVcIRiGrTIKziKcupVe5DdrWjajQd4EUNDlSwRfP2F67bMMLxtHNBygo4tNQNlUFUADNwujMK-3LhGW3X9e4kW2cml5cGcw6CBATATEEiBkASdj7zZSfA9XG3wYfEWSbgcSSHS-g7phRd8y_dCdhb28BN2hVtFUCbVj2KyNKXctaSq0S9nxQgM2rigKDNpQiYdWOauzIsnunXXyPzN24Opaiki__h_Cv2H1B9TVZnubla7bXXffhDQZInT2ItvALjnkPmQ
  priority: 102
  providerName: Directory of Open Access Journals
Title The Therapeutic Efficacy of Curcumin vs. Metformin in Modulating the Gut Microbiota in NAFLD Rats: A Comparative Study
URI https://www.ncbi.nlm.nih.gov/pubmed/33584555
https://www.proquest.com/docview/2489595586
https://pubmed.ncbi.nlm.nih.gov/PMC7874275
https://doaj.org/article/d1a530e582924a5dac6b1838ba6edffd
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1ba9swFBZdx2AvY_d5l6LBngYOtmzJ8mCMLGtaxtyH0UDejG7uAp3dJnZZ_v3OkZ10GWEMQiCOZBl_5-h8x5K_Q8i7uIoTm0sXZkJDgqK0DpUxPBRG5coIZpkXqy7OxOks_Trn8wOyKW813MDV3tQO60nNlpejX9frT-DwHzHjhHgLCCyMhlSPRSPOOcSvO-QuBKYMCxoUA9v3EzPmSv6llFgIXA9g836dc_9ZdiKVF_Tfx0L_3kz5R3SaPiQPBlpJx70dPCIHrn5M7vWFJtdPyA1YAz2_fdWKHqNyhDJr2lR00i1N93NR05vViBauRRoLv-BTNNZX96ovKPBEetK1tFj0yk2twgZn4-m3L_S7alcf6JhObpXEKe5PXD8ls-nx-eQ0HCouhAZ8sYWsNLIY00TFY-vAnW1kBaCV8CziymgAXKbcilg7qfOKZRDcFGfY2WvFJ8_IYd3U7gWhwAOcSpASSpVWWaZUorAX0DcrpE0DEm3ubmkGOXKsinFZQlqCgJQekBIBKXtAAvJ-2-Wq1-L4V-PPCNm2Icpo-wPN8qIcvLK0seJJ5LhkkIYqbsE6NcxxUivhbFXZgLzdAF6C2-Faiqpd061Klsqc55xLEZDnvQFsh0oSYHVwFQHJdkxj51p2_6kXP7y0N0yfKcv4y_8Y9xW5z3B_TRSHcfqaHLbLzr0BgtTqI_9gAb5P5vGRd4HfkQcPsQ
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Therapeutic+Efficacy+of+Curcumin+vs.+Metformin+in+Modulating+the+Gut+Microbiota+in+NAFLD+Rats%3A+A+Comparative+Study&rft.jtitle=Frontiers+in+microbiology&rft.au=Li%2C+Ruifang&rft.au=Yao%2C+Yurong&rft.au=Gao%2C+Pengfei&rft.au=Bu%2C+Shurui&rft.date=2021-01-14&rft.issn=1664-302X&rft.eissn=1664-302X&rft.volume=11&rft.spage=555293&rft_id=info:doi/10.3389%2Ffmicb.2020.555293&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-302X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-302X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-302X&client=summon